Skip to content
Peptigraph home

Amycretin Phase 2 trial (NCT06064006)

A Randomised, Placebo-controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0487-0111 in Participants With Overweight or Obesity

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
125
actual
Start
15 Sep 2023 (actual)
Primary completion
27 Nov 2024 (actual)
Sponsor
Novo Nordisk A/S
Design

Arms and doses

NCT06064006 study arms
ArmTypeInterventionsDescription
NNC0487-0111ExperimentalDrug: NNC0487-0111; Drug: Placebo (NNC0487-0111)Participants will be randomized to receive NNC0487-0111. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD) Part B, C, D and E: Multiple ascending dose (MAD)
PlaceboPlacebo comparatorDrug: NNC0487-0111; Drug: Placebo (NNC0487-0111)Participants will be randomized to receive Placebo. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD). Part B,C,D and E: Multiple ascending dose (MAD).
Endpoints

Primary endpoint

NCT06064006 primary outcomes
MeasureTime frame
PART A: Number of treatment emergent adverse events (TEAE)From pre-dose on Day 1 until completion of the end of study visit, up to Day 25
PARTS B to E: Number of treatment emergent adverse events (TEAE)From pre-dose on Day 1 until completion of the end of study visit (V37) up to Day 270
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT06064006 secondary outcomes
MeasureTime frame
PART A: AUC0-∞,SD; the area under the NNC0487-0111 plasma concentration-time curve from time 0 to infinity after a single doseFrom pre-dose on Day 1 until completion of the end of study visit, up to Day 25
PART A: Cmax,SD; the maximum plasma concentration of NNC0487-0111 after a single dose and the corresponding time tmaxFrom pre-dose on Day 1 until completion of the end of study visit, up to Day 25
PARTS B to E: AUC0-168h,SS; the area under the NNC0487-0111 plasma concentration-time curve from time 0 to 168 hours after last multiple doseFrom pre-dose on V33D1 until end of treatment (V34) up to 9 days
PARTS B to E: Cmax,SS; the maximum plasma concentration of NNC0487-0111 after last multiple dose and the corresponding time tmaxFrom pre-dose on V33D1 until end of study visit (V37) up to 24 days
PART B to E: Relative change in body weightFrom pre-dose on Day 1 until end of treatment (V34) up to Day 255
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
55 Years
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Randomised, Placebo-controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0487-0111 in Participants With Overweight or ObesityClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.